Serum NSE is currently believed to be a clinically potential biomarker for staging, monitoring treatment, and predicting relapse of SCLC.196,197 Interestingly, NSE also exerts a significant function in NSCLC. This evidence concerns the gene ENO2 and non-small cell lung carcinoma.